13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001306923
Total reported value
$723.7M
$723.7M
45 檔
34.3%
In Q2 2025, Palo Alto Investors LP's U.S. equity holdings reached a combined market value of $723.7M, distributed across 45 disclosed stock positions.
In Q2 2025, Palo Alto Investors LP adopted a defensive or profit-taking posture, trimming 15 positions and completely liquidating 6 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | INSM | Insmed Inc | Stock-Healthcare | 18.52% | -4.29% | -12.36% | |
| 2 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 11.76% | +0.23% | -3.78% | |
| 3 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 9.83% | -0.52% | -15.21% | |
| 4 | AM6 | Amicus Therapeutics Inc | Stock-Other | 6.84% | -2.46% | EXIT | |
| 5 | UTHR | United Therapeutics CORP | Stock-Healthcare | 5.84% | -1.01% | -9.26% | |
| 6 | BIIB | Biogen Inc | Stock-Healthcare | 5.50% | +0.24% | +0.41% | |
| 7 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 5.24% | — | -9.53% | |
| 8 | PTCT | Ptc Therapeutics Inc | Stock-Healthcare | 4.22% | +0.76% | +0.56% | |
| 9 | ANAB | Anaptysbio Inc | Stock-Other | 3.84% | +0.22% | -20.37% | |
| 10 | NVCR | NovoCure Limited | Stock-Healthcare | 3.64% | +0.55% | -3.96% | |
| 11 | STAA | Staar Surgical Co | Stock-Other | 2.83% | — | +50.83% | |
| 12 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 1.90% | -0.01% | -2.82% | |
| 13 | PRTA | Prothena Corporation plc | Stock-Other | 1.65% | -0.25% | -23.20% | |
| 14 | IRON | Disc Medicine Inc | Stock-Other | 1.64% | +0.28% | — | |
| 15 | ALGN | Align Technology Inc | Stock-Healthcare | 1.52% | -0.36% | — | |
| 16 | GOSS | Gossamer Bio Inc | Stock-Other | 1.50% | — | -8.57% | |
| 17 | EHTH | Ehealth Inc | Stock-Other | 1.46% | +0.02% | -6.32% | |
| 18 | ALKS | Alkermes plc | Stock-Healthcare | 1.35% | +0.45% | -0.22% | |
| 19 | IOVA | Iovance Biotherapeutics Inc | Stock-Other | 1.25% | -0.37% | +6.79% | |
| 20 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 0.89% | -0.48% | — | |
| 21 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 0.72% | — | — | |
| 22 | DNLI | Denali Therapeutics Inc | Stock-Other | 0.71% | -0.69% | EXIT | |
| 23 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 0.70% | +1.05% | — | |
| 24 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 0.66% | +0.01% | — | |
| 25 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.61% | +0.36% | -12.22% | |
| 26 | BNTX | Biontech Se-adr | Stock-Other | 0.57% | -0.02% | — | |
| 27 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.54% | +0.48% | -20.52% | |
| 28 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 0.46% | +0.01% | — | |
| 29 | ACRS | Aclaris Therapeutics Inc | Stock-Other | 0.42% | +0.25% | +79.12% | |
| 30 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.38% | +0.84% | — | |
| 31 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 0.37% | -0.02% | — | |
| 32 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 0.36% | +0.06% | — | |
| 33 | TVTX | Travere Therapeutics Inc | Stock-Other | 0.35% | +0.27% | — | |
| 34 | NUVB | Nuvation Bio Inc | Stock-Other | 0.32% | -0.07% | — | |
| 35 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.30% | -0.04% | — | |
| 36 | PYXS | Pyxis Oncology Inc | Stock-Other | 0.24% | +0.13% | — | |
| 37 | HUM | Humana Inc | Stock-Healthcare | 0.21% | +0.11% | — | |
| 38 | ALDX | Aldeyra Therapeutics Inc | Stock-Other | 0.18% | +0.01% | — | |
| 39 | KPTI | Karyopharm Therapeutics Inc | Stock-Other | 0.17% | — | — | |
| 40 | VYNE | Vyne Therapeutics Inc | Stock-Other | 0.16% | — | — | |
| 41 | ABEO | Abeona Therapeutics Inc | Stock-Other | 0.13% | +0.02% | — | |
| 42 | ALMS | Alumis Inc | Stock-Other | 0.09% | — | — | |
| 43 | URGN | UroGen Pharma Ltd. | Stock-Other | 0.07% | +0.05% | — | |
| 44 | ✓ | Akari Therapeutics PLC | Stock-Other | 0.04% | — | — | |
| 45 | GBIOGBX | Generation Bio Co | Stock-Other | 0.01% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | INSM | Insmed Inc | +4.2% | -12.36% | Trim |
| 2 | ACAD | Acadia Pharmaceuticals Inc | +3.3% | -3.78% | Trim |
| 3 | IRON | Disc Medicine Inc | +1.6% | NEW | New buy |
| 4 | STAA | Staar Surgical Co | +1.1% | +50.83% | Add |
| 5 | ALNY | Alnylam Pharmaceuticals Inc | +1% | -9.53% | Trim |
| 6 | RNAGBP | Avidity Biosciences Inc | +0.7% | NEW | New buy |
| 7 | DNLI | Denali Therapeutics Inc | +0.7% | NEW | New buy |
| 8 | CRSP | CRISPR Therapeutics AG | +0.5% | NEW | New buy |
| 9 | RARE | Ultragenyx Pharmaceutical In | +0.4% | NEW | New buy |
| 10 | ALGN | Align Technology Inc | +0.4% | — | Unchanged |
| 11 | AGIO | Agios Pharmaceuticals Inc | +0.4% | -2.82% | Trim |
| 12 | PTCT | Ptc Therapeutics Inc | +0.3% | +0.56% | Add |
| 13 | NVCR | NovoCure Limited | +0.2% | -3.96% | Trim |
| 14 | ANAB | Anaptysbio Inc | +0.2% | -20.37% | Trim |
| 15 | TSHA | Taysha Gene Therapies Inc | +0.2% | -12.22% | Trim |
| 16 | ACRS | Aclaris Therapeutics Inc | +0.2% | +79.12% | Add |
| 17 | GOSS | Gossamer Bio Inc | +0.2% | -8.57% | Trim |
| 18 | KPTI | Karyopharm Therapeutics Inc | +0.2% | NEW | New buy |
| 19 | BIIB | Biogen Inc | +0.2% | +0.41% | Add |
| 20 | STOK | Stoke Therapeutics Inc | +0.1% | — | Unchanged |
| 21 | MIRM | Mirum Pharmaceuticals Inc | +0.1% | — | Unchanged |
| 22 | BNTX | Biontech Se-adr | +0.1% | — | Unchanged |
| 23 | EW | Edwards Lifesciences CORP | +0.1% | — | Unchanged |
| 24 | ALMS | Alumis Inc | +0.1% | NEW | New buy |
| 25 | NBIX | Neurocrine Biosciences Inc | +0.1% | — | Unchanged |
| 26 | NUVB | Nuvation Bio Inc | +0.1% | — | Unchanged |
| 27 | PYXS | Pyxis Oncology Inc | +0.1% | — | Unchanged |
| 28 | ABEO | Abeona Therapeutics Inc | 0% | — | Unchanged |
| 29 | VYNE | Vyne Therapeutics Inc | 0% | — | Unchanged |
| 30 | URGN | UroGen Pharma Ltd. | 0% | — | Unchanged |
| 31 | HUM | Humana Inc | 0% | — | Unchanged |
| 32 | ✓ | Akari Therapeutics PLC | 0% | — | Unchanged |
| 33 | GBIOGBX | Generation Bio Co | — | — | Unchanged |
| 34 | BCYC | Bicycle Therapeutics Plc-adr | 0% | — | Unchanged |
| 35 | TVTX | Travere Therapeutics Inc | 0% | — | Unchanged |
| 36 | RLMD | Relmada Therapeutics Inc | 0% | EXIT | Sold out |
| 37 | ALKS | Alkermes plc | 0% | -0.22% | Trim |
| 38 | TIL | Instil Bio Inc | 0% | EXIT | Sold out |
| 39 | ALDX | Aldeyra Therapeutics Inc | -0.1% | — | Unchanged |
| 40 | DYN | Dyne Therapeutics Inc | -0.1% | -20.52% | Trim |
| 41 | SNDX | Syndax Pharmaceuticals Inc | -0.2% | — | Unchanged |
| 42 | KPTIEUR | Karyopharm Therapeutics Inc | -0.2% | EXIT | Sold out |
| 43 | UTHR | United Therapeutics CORP | -0.3% | -9.26% | Trim |
| 44 | ✓ | Verve Therapeutics Inc | -0.5% | EXIT | Sold out |
| 45 | EHTH | Ehealth Inc | -0.7% | -6.32% | Trim |
| 46 | IOVA | Iovance Biotherapeutics Inc | -0.8% | +6.79% | Add |
| 47 | ✓ | Acelyrin Inc | -0.8% | EXIT | Sold out |
| 48 | PRTA | Prothena Corporation plc | -2.3% | -23.20% | Trim |
| 49 | SRPT | Sarepta Therapeutics Inc | -2.6% | EXIT | Sold out |
| 50 | BMRN | Biomarin Pharmaceutical Inc | -3.5% | -15.21% | Trim |
According to official SEC Form 13F filings, Palo Alto Investors LP reported a total U.S. public equity portfolio value of $723.7M across 45 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including INSM, ACAD, BMRN) accounted for 34.3% of total reported equity market value during Q2 2025.
Top New Position Initiated
IRON
市值: $7.7M
Top Position Liquidated / Trimmed
SRPT
前期市值: $13.4M
During Q2 2025, Palo Alto Investors LP's top holdings by market value included INSM (18.5%)、ACAD (11.8%)、BMRN (9.8%). The largest single position, INSM, represented 18.5% of total portfolio value.
In Q2 2025, Palo Alto Investors LP made 33 total portfolio adjustments, initiating 7 new buys, adding to 5 positions, trimming 15 holdings, and fully liquidating 6 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.